PA
ITOS

Profund Advisors’s iTeos Therapeutics ITOS Stock Holding History

Profund Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,429
Closed -$169K – 1141
2023
Q3 		$169K Sell
15,429
-1,394
-8% -$17.8K 0.01% 907
2023
Q2 		$223K Sell
16,823
-5,347
-24% -$76.2K 0.01% 907
2023
Q1 		$302K Buy
+22,170
New +$397K 0.02% 724

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Profund Advisors's ITOS Position: Q4 2023 in Review

Profund Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 15,429 shares — an estimated $169K sold.

Profund Advisors first reported a position in ITOS in Q1 2023 and held it in 3 quarters. The position peaked at $302K in Q1 2023. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Profund Advisors reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Profund Advisors sold 15,429 iTeos Therapeutics shares in Q4 2023, an estimated $169K.
  • Profund Advisors first reported a position in iTeos Therapeutics in Q1 2023 and held it in 3 quarters.
  • Profund Advisors's iTeos Therapeutics position peaked at $302K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Profund Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.